BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Omni Bio Pharmaceutical to Present at Noble Financial Capital Markets' Eighth Annual Equity Conference on January 18


1/9/2012 10:09:31 AM

DENVER, CO--(Marketwire - January 09, 2012) - Omni Bio Pharmaceutical, Inc. ("Omni Bio") (OTCBB: OMBP), a clinical-stage biopharmaceutical company, today announced that it will present at Noble Financial Capital Markets' Eighth Annual Equity Conference being held January 17 & 18 at the Hard Rock Hotel & Casino in Hollywood, Florida.

Dr. James Crapo, Omni Bio's chief executive officer, is scheduled to speak on Wednesday, January 18 at 1:30 p.m. Eastern time (11:30 a.m. Mountain time).

Conference and presentation details will be made available at the Omni Bio website at www.omnibiopharma.com. An archived presentation will be available on the website for 30 days.

About Omni Bio Pharmaceutical, Inc.

Omni Bio Pharmaceutical, Inc. (www.omnibiopharma.com) is a clinical-stage biopharmaceutical company that has licensed potential new indications for an existing FDA approved drug -- Alpha-1 antitrypsin (AAT). Omni Bio's core technology is based on issued patents and patent applications licensed from the University of Colorado Denver (UCD) and a privately held company, Bio Holding, Inc. Omni Bio's lead development program has been funding research and a human clinical trial to evaluate the effectiveness of AAT in the treatment of Type 1 diabetes. Novel discoveries made at UCD indicate that AAT has the potential to address a variety of indications in the areas of diabetes, transplant rejection and bacterial and viral disorders.

Omni Bio is also a significant investor in BioMimetix Pharmaceutical, Inc. (BioMimetix), a recently formed biopharmaceutical corporation. BioMimetix is the exclusive licensee of an issued patent held by Duke University, and intends to develop a new class of patented compounds for the treatment of various diseases including radiation toxicity during the treatment of cancer using radiation therapy.


Omni Bio Pharmaceutical, Inc.
Bob Ogden
Chief Financial Officer - Investor Relations
(720) 488-4708
Email - investor_relations@omnibiopharma.com

WestMountain Asset Management

Steve Anderson - Public Relations
(970) 212-4770
Email - ir@westmountainam.com

Digg this    Bookmark with del.icio.us    Add to Newsvine

Technorati:


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->